NPPA Caps Trade Margins at 30% for 137 Anti-Cancer Drugs Effective November 9
India's National Pharmaceutical Pricing Authority (NPPA) has capped trade margins at 30% of the maximum retail price for 137 non-scheduled anti-cancer drugs, effective November 9. This measure aims to reduce excessive markups, potentially lowering retail prices by up to 70%. The list, recommended by an expert committee of oncologists and health officials, includes widely used immunotherapies and targeted therapies. Manufacturers must adjust prices accordingly, with compliance monitored by state drug controllers and hospitals. The list will be periodically updated to reflect market and public health needs.
First-hand measurement across 7 sources
We measured how 7 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (67/100). Lens Score 57/100.
Outlets measured: thestatesman, businessstandard, mint, moneycontrol, thetribune, news18, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 17 Oct, 02:29 pm. Other outlets followed.